Evaluation of Cerebrospinal Fluid and Plasma Biomarkers for Disease Progression in Parkinson’s Disease Using a Public Dataset
Keywords:
Parkinson’s Disease, α-synuclein, DJ-1, Neurofilament Light Chain, BiomarkersAbstract
Reduced levels of α-synuclein, DJ-1, and NfL in cerebrospinal fluid (CSF) and plasma, along with elevated inflammatory markers such as IL-1, IL-6, and TNF-α, have been frequently reported in Parkinson’s disease (PD). This study investigates the role of CSF and plasma biomarkers-α-synuclein, DJ-1, and Neurofilament Light Chain (NfL) using data obtained from the NeuroBioMark-PD Consortium Database, a publicly available anonymized dataset. A total of 60 participants were included: 40 PD patients and 20 healthy controls, all retained for analysis. Biomarker levels in both CSF and plasma were significantly elevated in PD patients compared to controls (p < 0.05). Strong positive correlations were observed between CSF α-synuclein and UPDRS-III motor scores (r = 0.72, p < 0.01), and between plasma DJ-1 and Hoehn and Yahr stage (r = 0.68, p < 0.01), highlighting their potential as biomarkers for disease severity and progression. These results support the clinical relevance of these biomarkers in PD diagnosis, monitoring, and potentially in guiding therapeutic strategies
Downloads
Metrics
References
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. doi:10.1016/S0140-6736(14)61393-3
Mollenhauer B, Trautmann E, Otte B, Ng J, Groschup S, Brockmann K, et al. α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm. 2012;119(7):739-46. doi:10.1007/s00702-012-0795-6
Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570-80. doi:10.1002/ana.22311
Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015;84(1):57-63. doi:10.1212/WNL.0000000000001098
Lin CH, Li CH, Yang KC, Chen ML, Chen PC, Chuang YC, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology. 2019;93(11):e1104-11. doi:10.1212/WNL.0000000000008084
Mielke MM, Maetzler W, Haughey NJ, Blennow K, Ballard C, Craig-Schapiro R, et al. Plasma biomarkers for Parkinson’s disease: progress and challenges. Mov Disord. 2021;36(11):2660-70. doi:10.1002/mds.28777
Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery CJ, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240-7. doi:10.1136/jnnp-2014-309540
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870-81. doi:10.1136/jnnp-2018-320106
Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson’s disease. Parkinsonism Relat Disord. 2014;20 Suppl 1:S99-103. doi:10.1016/S1353-8020(13)70025-1
Wang X, Yu S, Li F, Zhang Z, Chen Y, Wang Q, et al. Cerebrospinal fluid α-synuclein, total tau, and β-amyloid42 in Parkinson’s disease with cognitive impairment. Parkinsons Dis. 2016;2016:6475121. doi:10.1155/2016/6475121
Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorders. Neurology. 2017;88(10):930–7
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
